西达本胺单药治疗肝脾T细胞淋巴瘤  

Chidamide monotherapy for the treatment of hepatosplenic T-cell lymphoma:A case report

作　　者：侯理[1] 李通 马洪兵[1] 吴俣[1] HOU Li;LI Tong;MA Hongbing;WU Yu(Department of Hematology and Laboratory,Western China Hospital,Sichuan University,Chengdu 610041,China;Aerospace Center Hospital)

机构地区：[1]四川大学华西医院血液内科血液病研究室,四川成都610041 [2]航天中心医院

出　　处：《中国输血杂志》2021年第6期628-630,共3页Chinese Journal of Blood Transfusion

摘　　要：目的拟探索1种肝脾T细胞淋巴瘤(HSTCL)的有效治疗药物。方法本研究观察了1例2016年1月诊断为肝脾T细胞淋巴瘤的患者,由于一般情况不良,不适合接受传统化疗,故采用靶向药物西达本胺治疗。结果通过西达本胺单药治疗后情况获得惊人的改善,随访到目前为止,患者已获得部分缓解并能维持4年。结论该研究提示西达本胺是肝脾T细胞淋巴瘤患者治疗的1种新的选择。Objective To generate an efficacious therapeutic plan for patients suffered from Hepatosplenic T-cell lymphoma(HSTCL). Methods A patient diagnosed as HSTCL in January 2016 was observed, and chidamide monotherapy instead of traditional chemotherapy was applied due to the poor performance and infection complications of the patient. Results The patient has achieved amazing improvements after chidamide monotherapy. As we followed and evaluated recently, the patient has received partial remission and can keep durable remission for 4 years. Conclusion The study suggests that chidamide is a novel therapeuticchoice in patients with HSTCL.

关 键 词：肝脾T细胞淋巴瘤 西达本胺治疗 

分 类 号：R733[医药卫生—肿瘤] R457.1[医药卫生—临床医学]